Sale

Genomics Market

Global Genomics Market Size, Share, Growth, Trends, Analysis: By Deliverables: Product, Software and Services; By Technology: Sequencing, Microarray, Polymerase Chain Reaction (PCR), Nucleic Acid Extraction, Purification, Others; By Process; By Application; By End Users: Regional Analysis; Supplier Landscape; 2024-2032

Global Genomics Market Outlook

The global genomics market size was valued at USD 38.1 billion in 2023, driven by increased funding for genomic projects and the prevalence of chronic diseases across the globe. The market is expected to grow at a CAGR of 15.6% during the forecast period of 2024-2032, with the values likely to rise from USD 44 billion in 2024 to USD 140.1 billion by 2032.

 

Global Genomics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Genomics Market Overview

Genomics attempts to understand the genetic makeup of an organism and the downstream biological products. This branch of biology has emerged as the most impactful industry trend to treat and prevent diseases. The market demand is driven by multiple factors such as the increased demand for personalized medicine, gene therapy, and the prevalence of chronic diseases like cancer. A study published in Nature Medicine in January 2024  revealed that integrating clinical data with whole genome sequence data can pave the way for precision oncology. Consequently, it would help doctors provide customized treatment plans to patients suffering from cancer, leading to better patient outcomes.

 

The robust research activities have resulted in the development of a genomic data pool. This data can be utilized by physicians and biologists to find the genetic predisposition to certain diseases. It is expected that the clinical implementation of this genetic data pool will fuel the genomics market growth along with the evolution of a healthcare system that is more tailored to the patient’s needs.

 

Growth of Genome Editing-Based Therapeutics

The clinical application of genomics can improve the diagnostics system as well as provide personalized treatment options. The recent technological advancements in treatments, employing genomic editing holds the potential to improve the lives of many individuals. In January 2023, CAR-T cell therapy,  which works by using genetically modified T cells to identify and destroy specific cancer cells, cured a 13-year-old patient suffering from leukaemia.

 

The surge in approvals by the regularity authorities has further amplified the genomics market share. In November 2023, the UK Medicines and Health Regulatory Authority (MHRA)  approved a CRISPR-based gene therapy known as Casgevy or Exa-cel. This genome-edited cellular therapy utilizes the CRISPR/Cas9 system to produce healthy red blood cells in people with beta-thalassemia and sickle cell disease.

 

Increased Research Breakthroughs in Genomics

The growing research and clinical trials in the field of genomics, aided by increased funding and technological advancements have led to major research breakthroughs. In August 2023, a research article published in Nature revealed that scientists completed the sequencing of the human Y chromosome. It led to an addition of 30 million new bases in the human genome reference by end-to-end sequencing. The new research is poised to facilitate a better understanding of variation and associated diseases, offering improved therapeutic solutions to critical ailments.

 

Strategic Investments to Meet Genomics Market Demand

 

The rising investments by biotechnology firms to accelerate genomic research is expected to reflect significant implications in reshaping the market. In February 2023, Accenture Ventures  made a strategic investment in Ocean Genomics, a technology and AI company based in the United States to assist biopharma companies by creating computational platforms. The investment is expected to expedite the development of personalized medicines and artificial intelligence driven drug discovery. The incorporation of technological and scientific advancements in the healthcare system is anticipated to result in improved therapeutics and diagnostics fuelling the market growth.

 

Global Genomics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Genomics Market Segmentation

Market Breakup by Deliverables

  • Product
  • Software and Services

 

Market Breakup by Technology

  • Sequencing
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Nucleic Acid Extraction
  • Purification
  • Other

 

Market Breakup by Process

  • Library Preparation
  • Data Analysis
  • Others

 

Market Breakup by Application

  • Epigenomics
  • Functional
  • Biomarker Discovery
  • Pathway Analysis
  • Diagnostics
  • Drug Discovery
  • Development
  • Precision Medicine
  • Agriculture
  • Animal Research
  • Others

 

Market Breakup by End Users

  • Government and Academic Institutes
  • Clinical Research
  • Healthcare Facilities
  • Biotechnology and Pharmaceutical Companies
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Genomics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Genomics Market Regional Analysis

In North America, the robust healthcare system and increased funding for genomic projects are pushing the market growth. The prevalence of health issues in the region such as cancer, fuels the demand for genomic research in diagnostics and personalized medicine further. As a result, several pharmaceutical companies are collaborating or forming strategic alliances to deliver improved products and services to patients.

 

Europe holds a significant genomics market share which can be attributed to the existence of major research institutes and healthcare companies that play a pivotal role in increasing the market size.

 

The growing approvals of gene therapy treatments by health authorities and the evolving preference of patients for minimally invasive treatment procedures have further aided the market growth. In January 2024, Qiagen , a multinational provider of molecular testing solutions based in Germany, received the United States Food and Drug Administration (FDA) approval for NeuMoDx CT/NG Assay employing integrated PCR-based clinical molecular testing system, NeuMoDx 96 and 288 Molecular Systems. This assay utilizing fully automated analysers is designed to provide a rapid and precise diagnosis of sexually transmitted infection (STI).

 

Global Genomics Market: Competitor Landscape

In January 2024, Veracyte,  a global diagnostics company headquartered in the United States, acquired C2i Genomics, a biotechnology company based in Israel known for its minimal residual disease (MRD) tests in a USD 95 million deal. This acquisition aims to employ AI-assisted whole-genome MRD tests to expand the cancer diagnostics range. Thus, the boost in genomic research is supported by major investments in acquisitions, mergers, and expansions by the top biotechnology firms. Consequently, the genomics market value is expected to witness a surge in the forecast period.

 

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Eppendorf SE
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Freenome Holdings, Inc.
  • Myriad Genetics
  • Oxford Nanopore Technologies
  • PacBio
  • QIAGEN
  • Thermo Fisher Scientific
  • 23andMe
  • FOUNDATION MEDICINE
  • IntegraGen
  • Genome Diagnostics Pvt. Ltd
  • Cytiva

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Deliverables
  • Technology
  • Process
  • Application
  • End Users
  • Region
Breakup by Deliverables
  • Product
  • Software and Services
Breakup by Technology
  • Sequencing
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Nucleic Acid Extraction
  • Purification
  • Others
Breakup by Process
  • Library Preparation
  • Data Analysis
  • Others
Breakup by Application
  • Epigenomics
  • Functional
  • Biomarker Discovery
  • Pathway Analysis
  • Diagnostics
  • Drug Discovery
  • Development
  • Precision Medicine
  • Agriculture
  • Animal Research
  • Others
Breakup by End Users
  • Government and Academic Institutes
  • Clinical Research
  • Healthcare Facilities
  • Biotechnology and Pharmaceutical Companies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Eppendorf SE
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Freenome Holdings, Inc.
  • Myriad Genetics
  • Oxford Nanopore Technologies
  • PacBio
  • QIAGEN
  • Thermo Fisher Scientific
  • 23andMe
  • FOUNDATION MEDICIN
  • IntegraGen
  • Genome Diagnostics Pvt. Ltd
  • Cytiva

 

Genomics Market Report Snapshots

Genomics Market Size

Genomics Analysis

Genomics Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Genomics Market Overview 

    3.1    Global Genomics Historical Value (2017-2023) 
    3.2    Global Genomics Forecast Value (2024-2032)
4    Global Genomics Market Landscape
    4.1    Global Genomics Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Genomics Product Landscape
        4.2.1    Analysis by Technology 
        4.2.2    Analysis by Application 
5    Global Genomics Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
6    Global Genomics Market Segmentation (2017-2032)
    6.1    Global Genomics Market (2017-2032) by Deliverables
        6.1.1    Market Overview
        6.1.2    Product
        6.1.3    Software and Services
    6.2    Global Genomics Market (2017-2032) by Technology
        6.2.1    Market Overview 
        6.2.2    Sequencing
        6.2.3    Microarray
        6.2.4    Polymerase Chain Reaction (PCR)
        6.2.5    Nucleic Acid Extraction
        6.2.6    Purification
        6.2.7    Others
    6.3    Global Genomics Market (2017-2032) by Process
        6.3.1    Market Overview
        6.3.2    Library Preparation
        6.3.3    Data Analysis
        6.3.4    Others
    6.4    Global Genomics Market (2017-2032) by Application
        6.4.1    Market Overview
        6.4.2    Epigenomics
        6.4.3    Functional
        6.4.4    Biomarker Discovery
        6.4.5    Pathway Analysis
        6.4.6    Diagnostics
        6.4.7    Drug Discovery
        6.4.8    Development
        6.4.9    Precision Medicine
        6.4.10    Agriculture
        6.4.11    Animal Research
        6.4.12    Others
    6.5    Global Genomics Market (2017-2032) by End Users
        6.5.1    Market Overview
        6.5.2    Government and Academic Institutes
        6.5.3    Clinical Research
        6.5.4    Healthcare Facilities
        6.5.5    Biotechnology and Pharmaceutical Companies
        6.5.6    Others
    6.6    Global Genomics Market (2017-2032) by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Genomics Market (2017-2032)
    7.1    North America Genomics Market (2017-2032) by Deliverables 
        7.1.1    Market Overview    
        7.1.2    Product
        7.1.3    Software and Services
    7.2    North America Genomics Market (2017-2032) by Technology 
        7.2.1    Market Overview    
        7.2.2    Sequencing
        7.2.3    Microarray
        7.2.4    Polymerase Chain Reaction (PCR)
        7.2.5    Nucleic Acid Extraction
        7.2.6    Purification
        7.2.7    Others
    7.3    North America Genomics Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Genomics Market (2017-2032)
    8.1    Europe Genomics Market (2017-2032) by Deliverables
        8.1.1    Market Overview    
        8.1.2    Product
        8.1.3    Software and Services
    8.2    Europe Genomics Market (2017-2032) by Technology
        8.2.1    Market Overview    
        8.2.2    Sequencing
        8.2.3    Microarray
        8.2.4    Polymerase Chain Reaction (PCR)
        8.2.5    Nucleic Acid Extraction
        8.2.6    Purification
        8.2.7    Others
    8.3    Europe Genomics Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Genomics Market (2017-2032)
    9.1    Asia Pacific Genomics Market (2017-2032) by Deliverables
        9.1.1    Market Overview    
        9.1.2    Product
        9.1.3    Software and Services
    9.2    Asia Pacific Genomics Market (2017-2032) by Technology
        9.2.1    Market Overview    
        9.2.2    Sequencing
        9.2.3    Microarray
        9.2.4    Polymerase Chain Reaction (PCR)
        9.2.5    Nucleic Acid Extraction
        9.2.6    Purification
        9.2.7    Others
    9.3    Asia Pacific Genomics Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Genomics Market (2017-2032)
    10.1     Latin America Genomics Market (2017-2032) by Deliverables
        10.1.1    Market Overview    
        10.1.2    Product
        10.1.3    Software and Services
    10.2     Latin America Genomics Market (2017-2032) by Technology
        10.2.1    Market Overview    
        10.2.2    Sequencing
        10.2.3    Microarray
        10.2.4    Polymerase Chain Reaction (PCR)
        10.2.5    Nucleic Acid Extraction
        10.2.6    Purification
        10.2.7    Others
    10.3    Latin America Genomics Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Genomics Market (2017-2032)
    11.1     Middle East and Africa Genomics Market (2017-2032) by Deliverables
        11.1.1    Market Overview    
        11.1.2    Product
        11.1.3    Software and Services
    11.2    Middle East and Africa Genomics Market (2017-2032) by Technology
        11.2.1    Market Overview    
        11.2.2    Sequencing
        11.2.3    Microarray
        11.2.4    Polymerase Chain Reaction (PCR)
        11.2.5    Nucleic Acid Extraction
        11.2.6    Purification
        11.2.7    Others
    11.3    Middle East and Africa Genomics Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1     Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1    Analysis by Type of Patent
    13.2    Analysis by Publication Year
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Patent Age
    13.5    Analysis by CPC Analysis
    13.6    Analysis by Patent Valuation 
    13.7    Analysis by Key Players
14    Grants Analysis
    14.1    Analysis by Year
    14.2    Analysis by Amount Awarded
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Grant Application
    14.5    Analysis by Funding Institute
    14.6    Analysis by NIH Departments
    14.7    Analysis by Recipient Organization 
15    Clinical Trials Analysis 
    15.1     Analysis by Trial Registration Year 
    15.2    Analysis by Trial Status 
    15.3    Analysis by Trial Phase 
    15.4    Analysis by Therapeutic Area 
    15.5    Analysis by Geography 
16    Funding Analysis by Funding Instances
    16.1    Analysis by Type of Funding
    16.2    Analysis by Funding Amount
    16.3    Analysis by Leading Players
    16.4    Analysis by Leading Investors
    16.5    Analysis by Geography
17    Partnership and Collaborations Analysis
    17.1    Analysis by Partnership Instances
    17.2    Analysis by Type of Partnership
    17.3    Analysis by Leading Players
    17.4    Analysis by Geography
18    Supplier Landscape
    18.1     Eppendorf SE
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Eurofins Scientific
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3     F. Hoffmann-La Roche Ltd
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    GE Healthcare
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Freenome Holdings, Inc.
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Myriad Genetics
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Oxford Nanopore Technologies
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
    18.8    PacBio
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    QIAGEN
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Thermo Fisher Scientific
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    23andMe
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    FOUNDATION MEDICIN
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    IntegraGen
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14     Genome Diagnostics Pvt. Ltd
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
    18.15    Cytiva
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisitions
        18.15.5    Certifications
List not exhaustive

19    Global Genomics Market- Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies 
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.


* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
 

Key Questions Answered in the Report

The market attained a value of about USD 38.1 billion in 2023 driven by increased funding for genomic projects and the prevalence of chronic diseases across the globe.

The market is anticipated to grow at a CAGR of 15.6% during the forecast period of 2024-2032, likely to reach a market value of USD 140.1 billion by 2032.

The market demand is driven by the increasing prevalence of chronic diseases and the surge in funding and investments in research and development activities in the field of genomics.  

The development in minimally invasive cancer screening-based research and growing clinical trials are some of the key trends in the genomics market. In January 2024, Veracyte, a global diagnostics company acquired an Israel-based biotechnology company, C2i Genomics, to expand its cancer diagnostics range.

Product, software and services are major deliverables.

Based on the technology type, the market is divided into sequencing, microarray, polymerase chain reaction (PCR), nucleic acid extraction, purification, and others.

It includes library preparation, and data analysis among others.

Common application areas include epigenomics, functional, biomarker discovery, pathway analysis, diagnostics, drug discovery and development, precision medicine, agriculture, animal research and others. 

The various end users include government and academic institutes, clinical research centers, healthcare facilities, pharmaceutical and biotechnology companies, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

Key players involved in the market are Eppendorf SE, Eurofins Scientific, F. Hoffmann-La, Roche Ltd, GE Healthcare, Freenome Holdings, Inc., Myriad Genetics, Oxford Nanopore Technologies, PacBio, QIAGEN, Thermo Fisher Scientific, 23andMe, FOUNDATION MEDICINE, IntegraGen, Genome Diagnostics Pvt. Ltd and Cytiva.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER